Products & Services · Milestone payments paid
UHeart, UKidney, and UThymoKidney — Milestone payments paid
United Therapeutics UHeart, UKidney, and UThymoKidney — Milestone payments paid remained flat by 0.0% to $625.00K in Q4 2025 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryEfficiency
SignalHigher is better
VolatilityVolatile
First reportedQ1 2025
Last reportedQ4 2025
How to read this metric
Higher payments indicate active progress and successful achievement of development milestones, whereas zero or low payments may suggest delays or lack of progress in the program.
Detailed definition
This metric tracks the actual cash outflows made during the reporting period to satisfy contractual milestone obligation...
Peer comparison
Comparable to R&D milestone payments disclosed by other pharmaceutical companies in their cash flow statements or segment reporting.
Metric ID:
uthr_segment_uheart_ukidney_and_uthymokidney_milestone_payments_paidHistorical Data
1 years
| FY'25 | |
|---|---|
| Value | $2.50M |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is United Therapeutics's uheart, ukidney, and uthymokidney — milestone payments paid?
- United Therapeutics (UTHR) reported uheart, ukidney, and uthymokidney — milestone payments paid of $625.00K in Q4 2025.
- What does uheart, ukidney, and uthymokidney — milestone payments paid mean?
- The actual cash paid out during the year for achieving specific development or commercial milestones for these programs.